Long-term efficacy, safety and resistance analyses of entecavir (ETV) treatment in Japanese nucleoside-naive patients with chronic hepatitis B (CHB)

被引：0
|
作者：
Omata, M. [1 ]
Takaguchi, K. [2 ]
Fujioka, S. [3 ]
Hayashi, N. [4 ]
Shindo, M. [5 ]
Chayama, K. [6 ]
Ishikawa, H. [7 ]
Seriu, T. [8 ]
Kobashi, H. [9 ]
Yokosuka, O. [10 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan
[2] Kagawa Prefectural Cent Hosp, Dept Internal Med, Kagawa, Japan
[3] Okayama Saiseikai Gen Hosp, Dept Internal Med, Okayama, Japan
[4] Osaka Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Osaka, Japan
[5] Akashi Municipal Hosp, Dept Internal Med, Div Liver Dis, Akashi, Hyogo, Japan
[6] Hiroshima Univ, Grad Sch Biomed Sci, Dept Med & Mol Sci, Hiroshima, Japan
[7] Bristol Myers KK, Res & Dev, Tokyo, Japan
[8] Bristol Myers Squibb Co, Res & Dev, New York, NY 10154 USA
[9] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama, Japan
[10] Chiba Univ, Grad Sch Med, Dept Med & Clin Oncol, Chiba, Japan
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2008年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A30 / A30
页数：1
相关论文
共 50 条
  • [31] Long-term outcomes of entecavir monotherapy in patients with treatment-naive chronic hepatitis B
    Kim, Hyung Joon
    Lee, Hyun Woong
    Park, Ji Hoon
    Lee, Kyeong Heon
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 248 - 249
  • [32] Entecavir is well-tolerated for treatment of chronic hepatitis B: Phase III safety analysis in nucleoside-naive and lamivudine-refractory patients
    Sollano, J
    Schiff, E
    Carrilho, F
    Raptopoulou-Gigi, M
    Cooney, E
    Hindes, R
    Cross, A
    DeHertogh, D
    ANTIVIRAL THERAPY, 2004, 9 (06) : H24 - H24
  • [33] Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901
    Manns, Michael P.
    Akarca, Ulus S.
    Chang, Ting-Tsung
    Sievert, William
    Yoon, Seung Kew
    Tsai, Naoky
    Min, Albert
    Pangerl, Andreas
    Beebe, Suzanne
    Yu, Miao
    Wongcharatrawee, Suchat
    EXPERT OPINION ON DRUG SAFETY, 2012, 11 (03) : 361 - 368
  • [34] The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B
    Lurie, Y
    Manns, MP
    Gish, RG
    Chang, TT
    Yurdaydin, C
    Lai, CL
    Shouval, D
    Brown, RS
    Apelian, D
    Fernandes, L
    Klesczewski, K
    Cross, A
    Wilber, R
    JOURNAL OF HEPATOLOGY, 2005, 42 : 184 - 184
  • [35] Entecavir resistance is rare in nucleoside naive patients with hepatitis B
    Colonno, Richard J.
    Rose, Ronald
    Baldick, Carl J.
    Levine, Steven
    Pokornowski, Kevin
    Yu, Cheng F.
    Walsh, Ann
    Fang, Jie
    Hsu, Mayla
    Mazzucco, Charles
    Eggers, Betsy
    Zhang, Sharon
    Plym, Mary
    Klesczewski, Kenneth
    Tenney, Daniel J.
    HEPATOLOGY, 2006, 44 (06) : 1656 - 1665
  • [36] Polymorphism of estrogen receptor alpha (ESR1) is associated with virological response to entecavir (ETV) in nucleoside-naive adult patients with chronic hepatitis B
    Zhang, T. -T.
    Ye, J.
    Xia, S. -L.
    Zhang, Y. -F.
    Su, Q.
    Zhang, Z. -H.
    Li, X.
    INFECTION, 2013, 41 (02) : 371 - 378
  • [37] Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B
    Gish, R. G.
    Chang, T. -T.
    Lai, C. -L.
    de Man, R.
    Gadano, A.
    Poordad, F.
    Yang, J.
    Brett-Smith, H.
    Tamez, R.
    JOURNAL OF VIRAL HEPATITIS, 2010, 17 (01) : 16 - 22
  • [38] Long term outcomes of entecavir therapy in treatment naive chronic hepatitis B patients
    Gill, Muzaffar
    Gill, Uzma
    Aziz, Hafsa
    Salman, Farah
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 191 - 191
  • [39] Entecavir demonstrates consistent responses among baseline subgroups in the treatment of nucleoside-naive, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B
    Brown, RS
    Lok, AS
    Gish, RG
    Schiff, ER
    Shouval, D
    Senturk, H
    Chang, TT
    Yurdaydin, C
    Apelian, D
    Fernandes, L
    Klesczewski, K
    Cross, AP
    Wilber, RB
    GASTROENTEROLOGY, 2005, 128 (04) : A737 - A738
  • [40] Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients
    Yao, G. B.
    Ren, H.
    Xu, D. Z.
    Zhou, X. Q.
    Jia, J. D.
    Wang, Y. M.
    Chen, C. W.
    JOURNAL OF VIRAL HEPATITIS, 2010, 17 : 51 - 58
12345